Bill Text: FL S1688 | 2022 | Regular Session | Introduced
Bill Title: Pharmaceutical Products Containing Cannabis
Spectrum: Partisan Bill (Republican 1-0)
Status: (Failed) 2022-03-14 - Died in Regulated Industries [S1688 Detail]
Download: Florida-2022-S1688-Introduced.html
Florida Senate - 2022 SB 1688 By Senator Gruters 23-01339-22 20221688__ 1 A bill to be entitled 2 An act relating to pharmaceutical products containing 3 cannabis; amending s. 893.03, F.S.; excluding cannabis 4 from Schedule I listing if it is contained within a 5 pharmaceutical product approved by the United States 6 Food and Drug Administration; providing an effective 7 date. 8 9 Be It Enacted by the Legislature of the State of Florida: 10 11 Section 1. Paragraph (c) of subsection (1) of section 12 893.03, Florida Statutes, is amended to read: 13 893.03 Standards and schedules.—The substances enumerated 14 in this section are controlled by this chapter. The controlled 15 substances listed or to be listed in Schedules I, II, III, IV, 16 and V are included by whatever official, common, usual, 17 chemical, trade name, or class designated. The provisions of 18 this section shall not be construed to include within any of the 19 schedules contained in this section any excluded drugs listed 20 within the purview of 21 C.F.R. s. 1308.22, styled “Excluded 21 Substances”; 21 C.F.R. s. 1308.24, styled “Exempt Chemical 22 Preparations”; 21 C.F.R. s. 1308.32, styled “Exempted 23 Prescription Products”; or 21 C.F.R. s. 1308.34, styled “Exempt 24 Anabolic Steroid Products.” 25 (1) SCHEDULE I.—A substance in Schedule I has a high 26 potential for abuse and has no currently accepted medical use in 27 treatment in the United States and in its use under medical 28 supervision does not meet accepted safety standards. The 29 following substances are controlled in Schedule I: 30 (c) Unless specifically excepted or unless listed in 31 another schedule, any material, compound, mixture, or 32 preparation that contains any quantity of the following 33 hallucinogenic substances or that contains any of their salts, 34 isomers, including optical, positional, or geometric isomers, 35 homologues, nitrogen-heterocyclic analogs, esters, ethers, and 36 salts of isomers, homologues, nitrogen-heterocyclic analogs, 37 esters, or ethers, if the existence of such salts, isomers, and 38 salts of isomers is possible within the specific chemical 39 designation or class description: 40 1. Alpha-Ethyltryptamine. 41 2. 4-Methylaminorex (2-Amino-4-methyl-5-phenyl-2 42 oxazoline). 43 3. Aminorex (2-Amino-5-phenyl-2-oxazoline). 44 4. DOB (4-Bromo-2,5-dimethoxyamphetamine). 45 5. 2C-B (4-Bromo-2,5-dimethoxyphenethylamine). 46 6. Bufotenine. 47 7. Cannabis, except if it is contained within a 48 pharmaceutical product approved by the United States Food and 49 Drug Administration. 50 8. Cathinone. 51 9. DET (Diethyltryptamine). 52 10. 2,5-Dimethoxyamphetamine. 53 11. DOET (4-Ethyl-2,5-Dimethoxyamphetamine). 54 12. DMT (Dimethyltryptamine). 55 13. PCE (N-Ethyl-1-phenylcyclohexylamine) (Ethylamine 56 analog of phencyclidine). 57 14. JB-318 (N-Ethyl-3-piperidyl benzilate). 58 15. N-Ethylamphetamine. 59 16. Fenethylline. 60 17. 3,4-Methylenedioxy-N-hydroxyamphetamine. 61 18. Ibogaine. 62 19. LSD (Lysergic acid diethylamide). 63 20. Mescaline. 64 21. Methcathinone. 65 22. 5-Methoxy-3,4-methylenedioxyamphetamine. 66 23. PMA (4-Methoxyamphetamine). 67 24. PMMA (4-Methoxymethamphetamine). 68 25. DOM (4-Methyl-2,5-dimethoxyamphetamine). 69 26. MDEA (3,4-Methylenedioxy-N-ethylamphetamine). 70 27. MDA (3,4-Methylenedioxyamphetamine). 71 28. JB-336 (N-Methyl-3-piperidyl benzilate). 72 29. N,N-Dimethylamphetamine. 73 30. Parahexyl. 74 31. Peyote. 75 32. PCPY (N-(1-Phenylcyclohexyl)-pyrrolidine) (Pyrrolidine 76 analog of phencyclidine). 77 33. Psilocybin. 78 34. Psilocyn. 79 35. Salvia divinorum, except for any drug product approved 80 by the United States Food and Drug Administration which contains 81 Salvia divinorum or its isomers, esters, ethers, salts, and 82 salts of isomers, esters, and ethers, if the existence of such 83 isomers, esters, ethers, and salts is possible within the 84 specific chemical designation. 85 36. Salvinorin A, except for any drug product approved by 86 the United States Food and Drug Administration which contains 87 Salvinorin A or its isomers, esters, ethers, salts, and salts of 88 isomers, esters, and ethers, if the existence of such isomers, 89 esters, ethers, and salts is possible within the specific 90 chemical designation. 91 37. Xylazine. 92 38. TCP (1-[1-(2-Thienyl)-cyclohexyl]-piperidine) 93 (Thiophene analog of phencyclidine). 94 39. 3,4,5-Trimethoxyamphetamine. 95 40. Methylone (3,4-Methylenedioxymethcathinone). 96 41. MDPV (3,4-Methylenedioxypyrovalerone). 97 42. Methylmethcathinone. 98 43. Methoxymethcathinone. 99 44. Fluoromethcathinone. 100 45. Methylethcathinone. 101 46. CP 47,497 (2-(3-Hydroxycyclohexyl)-5-(2-methyloctan-2 102 yl)phenol) and its dimethyloctyl (C8) homologue. 103 47. HU-210 [(6aR,10aR)-9-(Hydroxymethyl)-6,6-dimethyl-3-(2 104 methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol]. 105 48. JWH-018 (1-Pentyl-3-(1-naphthoyl)indole). 106 49. JWH-073 (1-Butyl-3-(1-naphthoyl)indole). 107 50. JWH-200 (1-[2-(4-Morpholinyl)ethyl]-3-(1 108 naphthoyl)indole). 109 51. BZP (Benzylpiperazine). 110 52. Fluorophenylpiperazine. 111 53. Methylphenylpiperazine. 112 54. Chlorophenylpiperazine. 113 55. Methoxyphenylpiperazine. 114 56. DBZP (1,4-Dibenzylpiperazine). 115 57. TFMPP (Trifluoromethylphenylpiperazine). 116 58. MBDB (Methylbenzodioxolylbutanamine) or (3,4 117 Methylenedioxy-N-methylbutanamine). 118 59. 5-Hydroxy-AMT (5-Hydroxy-alpha-methyltryptamine). 119 60. 5-Hydroxy-N-methyltryptamine. 120 61. 5-MeO-MiPT (5-Methoxy-N-methyl-N-isopropyltryptamine). 121 62. 5-MeO-AMT (5-Methoxy-alpha-methyltryptamine). 122 63. Methyltryptamine. 123 64. 5-MeO-DMT (5-Methoxy-N,N-dimethyltryptamine). 124 65. 5-Me-DMT (5-Methyl-N,N-dimethyltryptamine). 125 66. Tyramine (4-Hydroxyphenethylamine). 126 67. 5-MeO-DiPT (5-Methoxy-N,N-Diisopropyltryptamine). 127 68. DiPT (N,N-Diisopropyltryptamine). 128 69. DPT (N,N-Dipropyltryptamine). 129 70. 4-Hydroxy-DiPT (4-Hydroxy-N,N-diisopropyltryptamine). 130 71. 5-MeO-DALT (5-Methoxy-N,N-Diallyltryptamine). 131 72. DOI (4-Iodo-2,5-dimethoxyamphetamine). 132 73. DOC (4-Chloro-2,5-dimethoxyamphetamine). 133 74. 2C-E (4-Ethyl-2,5-dimethoxyphenethylamine). 134 75. 2C-T-4 (4-Isopropylthio-2,5-dimethoxyphenethylamine). 135 76. 2C-C (4-Chloro-2,5-dimethoxyphenethylamine). 136 77. 2C-T (4-Methylthio-2,5-dimethoxyphenethylamine). 137 78. 2C-T-2 (4-Ethylthio-2,5-dimethoxyphenethylamine). 138 79. 2C-T-7 (4-(n)-Propylthio-2,5-dimethoxyphenethylamine). 139 80. 2C-I (4-Iodo-2,5-dimethoxyphenethylamine). 140 81. Butylone (3,4-Methylenedioxy-alpha 141 methylaminobutyrophenone). 142 82. Ethcathinone. 143 83. Ethylone (3,4-Methylenedioxy-N-ethylcathinone). 144 84. Naphyrone (Naphthylpyrovalerone). 145 85. Dimethylone (3,4-Methylenedioxy-N,N-dimethylcathinone). 146 86. 3,4-Methylenedioxy-N,N-diethylcathinone. 147 87. 3,4-Methylenedioxy-propiophenone. 148 88. 3,4-Methylenedioxy-alpha-bromopropiophenone. 149 89. 3,4-Methylenedioxy-propiophenone-2-oxime. 150 90. 3,4-Methylenedioxy-N-acetylcathinone. 151 91. 3,4-Methylenedioxy-N-acetylmethcathinone. 152 92. 3,4-Methylenedioxy-N-acetylethcathinone. 153 93. Bromomethcathinone. 154 94. Buphedrone (alpha-Methylamino-butyrophenone). 155 95. Eutylone (3,4-Methylenedioxy-alpha 156 ethylaminobutyrophenone). 157 96. Dimethylcathinone. 158 97. Dimethylmethcathinone. 159 98. Pentylone (3,4-Methylenedioxy-alpha 160 methylaminovalerophenone). 161 99. MDPPP (3,4-Methylenedioxy-alpha 162 pyrrolidinopropiophenone). 163 100. MDPBP (3,4-Methylenedioxy-alpha 164 pyrrolidinobutyrophenone). 165 101. MOPPP (Methoxy-alpha-pyrrolidinopropiophenone). 166 102. MPHP (Methyl-alpha-pyrrolidinohexanophenone). 167 103. BTCP (Benzothiophenylcyclohexylpiperidine) or BCP 168 (Benocyclidine). 169 104. F-MABP (Fluoromethylaminobutyrophenone). 170 105. MeO-PBP (Methoxypyrrolidinobutyrophenone). 171 106. Et-PBP (Ethylpyrrolidinobutyrophenone). 172 107. 3-Me-4-MeO-MCAT (3-Methyl-4-Methoxymethcathinone). 173 108. Me-EABP (Methylethylaminobutyrophenone). 174 109. Etizolam. 175 110. PPP (Pyrrolidinopropiophenone). 176 111. PBP (Pyrrolidinobutyrophenone). 177 112. PVP (Pyrrolidinovalerophenone) or 178 (Pyrrolidinopentiophenone). 179 113. MPPP (Methyl-alpha-pyrrolidinopropiophenone). 180 114. JWH-007 (1-Pentyl-2-methyl-3-(1-naphthoyl)indole). 181 115. JWH-015 (1-Propyl-2-methyl-3-(1-naphthoyl)indole). 182 116. JWH-019 (1-Hexyl-3-(1-naphthoyl)indole). 183 117. JWH-020 (1-Heptyl-3-(1-naphthoyl)indole). 184 118. JWH-072 (1-Propyl-3-(1-naphthoyl)indole). 185 119. JWH-081 (1-Pentyl-3-(4-methoxy-1-naphthoyl)indole). 186 120. JWH-122 (1-Pentyl-3-(4-methyl-1-naphthoyl)indole). 187 121. JWH-133 ((6aR,10aR)-6,6,9-Trimethyl-3-(2-methylpentan 188 2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromene). 189 122. JWH-175 (1-Pentyl-3-(1-naphthylmethyl)indole). 190 123. JWH-201 (1-Pentyl-3-(4-methoxyphenylacetyl)indole). 191 124. JWH-203 (1-Pentyl-3-(2-chlorophenylacetyl)indole). 192 125. JWH-210 (1-Pentyl-3-(4-ethyl-1-naphthoyl)indole). 193 126. JWH-250 (1-Pentyl-3-(2-methoxyphenylacetyl)indole). 194 127. JWH-251 (1-Pentyl-3-(2-methylphenylacetyl)indole). 195 128. JWH-302 (1-Pentyl-3-(3-methoxyphenylacetyl)indole). 196 129. JWH-398 (1-Pentyl-3-(4-chloro-1-naphthoyl)indole). 197 130. HU-211 ((6aS,10aS)-9-(Hydroxymethyl)-6,6-dimethyl-3 198 (2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1 199 ol). 200 131. HU-308 ([(1R,2R,5R)-2-[2,6-Dimethoxy-4-(2-methyloctan 201 2-yl)phenyl]-7,7-dimethyl-4-bicyclo[3.1.1]hept-3-enyl] 202 methanol). 203 132. HU-331 (3-Hydroxy-2-[(1R,6R)-3-methyl-6-(1 204 methylethenyl)-2-cyclohexen-1-yl]-5-pentyl-2,5-cyclohexadiene 205 1,4-dione). 206 133. CB-13 (4-Pentyloxy-1-(1-naphthoyl)naphthalene). 207 134. CB-25 (N-Cyclopropyl-11-(3-hydroxy-5-pentylphenoxy) 208 undecanamide). 209 135. CB-52 (N-Cyclopropyl-11-(2-hexyl-5-hydroxyphenoxy) 210 undecanamide). 211 136. CP 55,940 (2-[3-Hydroxy-6-propanol-cyclohexyl]-5-(2 212 methyloctan-2-yl)phenol). 213 137. AM-694 (1-(5-Fluoropentyl)-3-(2-iodobenzoyl)indole). 214 138. AM-2201 (1-(5-Fluoropentyl)-3-(1-naphthoyl)indole). 215 139. RCS-4 (1-Pentyl-3-(4-methoxybenzoyl)indole). 216 140. RCS-8 (1-(2-Cyclohexylethyl)-3-(2 217 methoxyphenylacetyl)indole). 218 141. WIN55,212-2 ((R)-(+)-[2,3-Dihydro-5-methyl-3-(4 219 morpholinylmethyl)pyrrolo[1,2,3-de]-1,4-benzoxazin-6-yl]-1 220 naphthalenylmethanone). 221 142. WIN55,212-3 ([(3S)-2,3-Dihydro-5-methyl-3-(4 222 morpholinylmethyl)pyrrolo[1,2,3-de]-1,4-benzoxazin-6-yl]-1 223 naphthalenylmethanone). 224 143. Pentedrone (alpha-Methylaminovalerophenone). 225 144. Fluoroamphetamine. 226 145. Fluoromethamphetamine. 227 146. Methoxetamine. 228 147. Methiopropamine. 229 148. Methylbuphedrone (Methyl-alpha 230 methylaminobutyrophenone). 231 149. APB ((2-Aminopropyl)benzofuran). 232 150. APDB ((2-Aminopropyl)-2,3-dihydrobenzofuran). 233 151. UR-144 (1-Pentyl-3-(2,2,3,3 234 tetramethylcyclopropanoyl)indole). 235 152. XLR11 (1-(5-Fluoropentyl)-3-(2,2,3,3 236 tetramethylcyclopropanoyl)indole). 237 153. Chloro UR-144 (1-(Chloropentyl)-3-(2,2,3,3 238 tetramethylcyclopropanoyl)indole). 239 154. AKB48 (N-Adamant-1-yl 1-pentylindazole-3-carboxamide). 240 155. AM-2233(1-[(N-Methyl-2-piperidinyl)methyl]-3-(2 241 iodobenzoyl)indole). 242 156. STS-135 (N-Adamant-1-yl 1-(5-fluoropentyl)indole-3 243 carboxamide). 244 157. URB-597 ((3′-(Aminocarbonyl)[1,1′-biphenyl]-3-yl) 245 cyclohexylcarbamate). 246 158. URB-602 ([1,1′-Biphenyl]-3-yl-carbamic acid, 247 cyclohexyl ester). 248 159. URB-754 (6-Methyl-2-[(4-methylphenyl)amino]-1 249 benzoxazin-4-one). 250 160. 2C-D (4-Methyl-2,5-dimethoxyphenethylamine). 251 161. 2C-H (2,5-Dimethoxyphenethylamine). 252 162. 2C-N (4-Nitro-2,5-dimethoxyphenethylamine). 253 163. 2C-P (4-(n)-Propyl-2,5-dimethoxyphenethylamine). 254 164. 25I-NBOMe (4-Iodo-2,5-dimethoxy-[N-(2 255 methoxybenzyl)]phenethylamine). 256 165. MDMA (3,4-Methylenedioxymethamphetamine). 257 166. PB-22 (8-Quinolinyl 1-pentylindole-3-carboxylate). 258 167. Fluoro PB-22 (8-Quinolinyl 1-(fluoropentyl)indole-3 259 carboxylate). 260 168. BB-22 (8-Quinolinyl 1-(cyclohexylmethyl)indole-3 261 carboxylate). 262 169. Fluoro AKB48 (N-Adamant-1-yl 1-(fluoropentyl)indazole 263 3-carboxamide). 264 170. AB-PINACA (N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1 265 pentylindazole-3-carboxamide). 266 171. AB-FUBINACA (N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1 267 (4-fluorobenzyl)indazole-3-carboxamide). 268 172. ADB-PINACA (N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl) 269 1-pentylindazole-3-carboxamide). 270 173. Fluoro ADBICA (N-(1-Amino-3,3-dimethyl-1-oxobutan-2 271 yl)-1-(fluoropentyl)indole-3-carboxamide). 272 174. 25B-NBOMe (4-Bromo-2,5-dimethoxy-[N-(2 273 methoxybenzyl)]phenethylamine). 274 175. 25C-NBOMe (4-Chloro-2,5-dimethoxy-[N-(2 275 methoxybenzyl)]phenethylamine). 276 176. AB-CHMINACA (N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1 277 (cyclohexylmethyl)indazole-3-carboxamide). 278 177. FUB-PB-22 (8-Quinolinyl 1-(4-fluorobenzyl)indole-3 279 carboxylate). 280 178. Fluoro-NNEI (N-Naphthalen-1-yl 1-(fluoropentyl)indole 281 3-carboxamide). 282 179. Fluoro-AMB (N-(1-Methoxy-3-methyl-1-oxobutan-2-yl)-1 283 (fluoropentyl)indazole-3-carboxamide). 284 180. THJ-2201 (1-(5-Fluoropentyl)-3-(1-naphthoyl)indazole). 285 181. AM-855 ((4aR,12bR)-8-Hexyl-2,5,5-trimethyl 286 1,4,4a,8,9,10,11,12b-octahydronaphtho[3,2-c]isochromen-12-ol). 287 182. AM-905 ((6aR,9R,10aR)-3-[(E)-Hept-1-enyl]-9 288 (hydroxymethyl)-6,6-dimethyl-6a,7,8,9,10,10a 289 hexahydrobenzo[c]chromen-1-ol). 290 183. AM-906 ((6aR,9R,10aR)-3-[(Z)-Hept-1-enyl]-9 291 (hydroxymethyl)-6,6-dimethyl-6a,7,8,9,10,10a 292 hexahydrobenzo[c]chromen-1-ol). 293 184. AM-2389 ((6aR,9R,10aR)-3-(1-Hexyl-cyclobut-1-yl) 294 6a,7,8,9,10,10a-hexahydro-6,6-dimethyl-6H-dibenzo[b,d]pyran-1,9 295 diol). 296 185. HU-243 ((6aR,8S,9S,10aR)-9-(Hydroxymethyl)-6,6 297 dimethyl-3-(2-methyloctan-2-yl)-8,9-ditritio-7,8,10,10a 298 tetrahydro-6aH-benzo[c]chromen-1-ol). 299 186. HU-336 ((6aR,10aR)-6,6,9-Trimethyl-3-pentyl 300 6a,7,10,10a-tetrahydro-1H-benzo[c]chromene-1,4(6H)-dione). 301 187. MAPB ((2-Methylaminopropyl)benzofuran). 302 188. 5-IT (2-(1H-Indol-5-yl)-1-methyl-ethylamine). 303 189. 6-IT (2-(1H-Indol-6-yl)-1-methyl-ethylamine). 304 190. Synthetic Cannabinoids.—Unless specifically excepted 305 or unless listed in another schedule or contained within a 306 pharmaceutical product approved by the United States Food and 307 Drug Administration, any material, compound, mixture, or 308 preparation that contains any quantity of a synthetic 309 cannabinoid found to be in any of the following chemical class 310 descriptions, or homologues, nitrogen-heterocyclic analogs, 311 isomers (including optical, positional, or geometric), esters, 312 ethers, salts, and salts of homologues, nitrogen-heterocyclic 313 analogs, isomers, esters, or ethers, whenever the existence of 314 such homologues, nitrogen-heterocyclic analogs, isomers, esters, 315 ethers, salts, and salts of isomers, esters, or ethers is 316 possible within the specific chemical class or designation. 317 Since nomenclature of these synthetically produced cannabinoids 318 is not internationally standardized and may continually evolve, 319 these structures or the compounds of these structures shall be 320 included under this subparagraph, regardless of their specific 321 numerical designation of atomic positions covered, if it can be 322 determined through a recognized method of scientific testing or 323 analysis that the substance contains properties that fit within 324 one or more of the following categories: 325 a. Tetrahydrocannabinols.—Any tetrahydrocannabinols 326 naturally contained in a plant of the genus Cannabis, the 327 synthetic equivalents of the substances contained in the plant 328 or in the resinous extracts of the genus Cannabis, or synthetic 329 substances, derivatives, and their isomers with similar chemical 330 structure and pharmacological activity, including, but not 331 limited to, Delta 9 tetrahydrocannabinols and their optical 332 isomers, Delta 8 tetrahydrocannabinols and their optical 333 isomers, Delta 6a,10a tetrahydrocannabinols and their optical 334 isomers, or any compound containing a tetrahydrobenzo[c]chromene 335 structure with substitution at either or both the 3-position or 336 9-position, with or without substitution at the 1-position with 337 hydroxyl or alkoxy groups, including, but not limited to: 338 (I) Tetrahydrocannabinol. 339 (II) HU-210 ((6aR,10aR)-9-(Hydroxymethyl)-6,6-dimethyl-3 340 (2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1 341 ol). 342 (III) HU-211 ((6aS,10aS)-9-(Hydroxymethyl)-6,6-dimethyl-3 343 (2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1 344 ol). 345 (IV) JWH-051 ((6aR,10aR)-9-(Hydroxymethyl)-6,6-dimethyl-3 346 (2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromene). 347 (V) JWH-133 ((6aR,10aR)-6,6,9-Trimethyl-3-(2-methylpentan 348 2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromene). 349 (VI) JWH-057 ((6aR,10aR)-6,6,9-Trimethyl-3-(2-methyloctan 350 2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromene). 351 (VII) JWH-359 ((6aR,10aR)-1-Methoxy-6,6,9-trimethyl-3-(2,3 352 dimethylpentan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromene). 353 (VIII) AM-087 ((6aR,10aR)-3-(2-Methyl-6-bromohex-2-yl) 354 6,6,9-trimethyl-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol). 355 (IX) AM-411 ((6aR,10aR)-3-(1-Adamantyl)-6,6,9-trimethyl 356 6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol). 357 (X) Parahexyl. 358 b. Naphthoylindoles, Naphthoylindazoles, 359 Naphthoylcarbazoles, Naphthylmethylindoles, 360 Naphthylmethylindazoles, and Naphthylmethylcarbazoles.—Any 361 compound containing a naphthoylindole, naphthoylindazole, 362 naphthoylcarbazole, naphthylmethylindole, 363 naphthylmethylindazole, or naphthylmethylcarbazole structure, 364 with or without substitution on the indole, indazole, or 365 carbazole ring to any extent, whether or not substituted on the 366 naphthyl ring to any extent, including, but not limited to: 367 (I) JWH-007 (1-Pentyl-2-methyl-3-(1-naphthoyl)indole). 368 (II) JWH-011 (1-(1-Methylhexyl)-2-methyl-3-(1 369 naphthoyl)indole). 370 (III) JWH-015 (1-Propyl-2-methyl-3-(1-naphthoyl)indole). 371 (IV) JWH-016 (1-Butyl-2-methyl-3-(1-naphthoyl)indole). 372 (V) JWH-018 (1-Pentyl-3-(1-naphthoyl)indole). 373 (VI) JWH-019 (1-Hexyl-3-(1-naphthoyl)indole). 374 (VII) JWH-020 (1-Heptyl-3-(1-naphthoyl)indole). 375 (VIII) JWH-022 (1-(4-Pentenyl)-3-(1-naphthoyl)indole). 376 (IX) JWH-071 (1-Ethyl-3-(1-naphthoyl)indole). 377 (X) JWH-072 (1-Propyl-3-(1-naphthoyl)indole). 378 (XI) JWH-073 (1-Butyl-3-(1-naphthoyl)indole). 379 (XII) JWH-080 (1-Butyl-3-(4-methoxy-1-naphthoyl)indole). 380 (XIII) JWH-081 (1-Pentyl-3-(4-methoxy-1-naphthoyl)indole). 381 (XIV) JWH-098 (1-Pentyl-2-methyl-3-(4-methoxy-1 382 naphthoyl)indole). 383 (XV) JWH-116 (1-Pentyl-2-ethyl-3-(1-naphthoyl)indole). 384 (XVI) JWH-122 (1-Pentyl-3-(4-methyl-1-naphthoyl)indole). 385 (XVII) JWH-149 (1-Pentyl-2-methyl-3-(4-methyl-1 386 naphthoyl)indole). 387 (XVIII) JWH-164 (1-Pentyl-3-(7-methoxy-1-naphthoyl)indole). 388 (XIX) JWH-175 (1-Pentyl-3-(1-naphthylmethyl)indole). 389 (XX) JWH-180 (1-Propyl-3-(4-propyl-1-naphthoyl)indole). 390 (XXI) JWH-182 (1-Pentyl-3-(4-propyl-1-naphthoyl)indole). 391 (XXII) JWH-184 (1-Pentyl-3-[(4-methyl)-1 392 naphthylmethyl]indole). 393 (XXIII) JWH-193 (1-[2-(4-Morpholinyl)ethyl]-3-(4-methyl-1 394 naphthoyl)indole). 395 (XXIV) JWH-198 (1-[2-(4-Morpholinyl)ethyl]-3-(4-methoxy-1 396 naphthoyl)indole). 397 (XXV) JWH-200 (1-[2-(4-Morpholinyl)ethyl]-3-(1 398 naphthoyl)indole). 399 (XXVI) JWH-210 (1-Pentyl-3-(4-ethyl-1-naphthoyl)indole). 400 (XXVII) JWH-387 (1-Pentyl-3-(4-bromo-1-naphthoyl)indole). 401 (XXVIII) JWH-398 (1-Pentyl-3-(4-chloro-1-naphthoyl)indole). 402 (XXIX) JWH-412 (1-Pentyl-3-(4-fluoro-1-naphthoyl)indole). 403 (XXX) JWH-424 (1-Pentyl-3-(8-bromo-1-naphthoyl)indole). 404 (XXXI) AM-1220 (1-[(1-Methyl-2-piperidinyl)methyl]-3-(1 405 naphthoyl)indole). 406 (XXXII) AM-1235 (1-(5-Fluoropentyl)-6-nitro-3-(1 407 naphthoyl)indole). 408 (XXXIII) AM-2201 (1-(5-Fluoropentyl)-3-(1 409 naphthoyl)indole). 410 (XXXIV) Chloro JWH-018 (1-(Chloropentyl)-3-(1 411 naphthoyl)indole). 412 (XXXV) Bromo JWH-018 (1-(Bromopentyl)-3-(1 413 naphthoyl)indole). 414 (XXXVI) AM-2232 (1-(4-Cyanobutyl)-3-(1-naphthoyl)indole). 415 (XXXVII) THJ-2201 (1-(5-Fluoropentyl)-3-(1 416 naphthoyl)indazole). 417 (XXXVIII) MAM-2201 (1-(5-Fluoropentyl)-3-(4-methyl-1 418 naphthoyl)indole). 419 (XXXIX) EAM-2201 (1-(5-Fluoropentyl)-3-(4-ethyl-1 420 naphthoyl)indole). 421 (XL) EG-018 (9-Pentyl-3-(1-naphthoyl)carbazole). 422 (XLI) EG-2201 (9-(5-Fluoropentyl)-3-(1 423 naphthoyl)carbazole). 424 c. Naphthoylpyrroles.—Any compound containing a 425 naphthoylpyrrole structure, with or without substitution on the 426 pyrrole ring to any extent, whether or not substituted on the 427 naphthyl ring to any extent, including, but not limited to: 428 (I) JWH-030 (1-Pentyl-3-(1-naphthoyl)pyrrole). 429 (II) JWH-031 (1-Hexyl-3-(1-naphthoyl)pyrrole). 430 (III) JWH-145 (1-Pentyl-5-phenyl-3-(1-naphthoyl)pyrrole). 431 (IV) JWH-146 (1-Heptyl-5-phenyl-3-(1-naphthoyl)pyrrole). 432 (V) JWH-147 (1-Hexyl-5-phenyl-3-(1-naphthoyl)pyrrole). 433 (VI) JWH-307 (1-Pentyl-5-(2-fluorophenyl)-3-(1 434 naphthoyl)pyrrole). 435 (VII) JWH-309 (1-Pentyl-5-(1-naphthalenyl)-3-(1 436 naphthoyl)pyrrole). 437 (VIII) JWH-368 (1-Pentyl-5-(3-fluorophenyl)-3-(1 438 naphthoyl)pyrrole). 439 (IX) JWH-369 (1-Pentyl-5-(2-chlorophenyl)-3-(1 440 naphthoyl)pyrrole). 441 (X) JWH-370 (1-Pentyl-5-(2-methylphenyl)-3-(1 442 naphthoyl)pyrrole). 443 d. Naphthylmethylenindenes.—Any compound containing a 444 naphthylmethylenindene structure, with or without substitution 445 at the 3-position of the indene ring to any extent, whether or 446 not substituted on the naphthyl ring to any extent, including, 447 but not limited to, JWH-176 (3-Pentyl-1 448 (naphthylmethylene)indene). 449 e. Phenylacetylindoles and Phenylacetylindazoles.—Any 450 compound containing a phenylacetylindole or phenylacetylindazole 451 structure, with or without substitution on the indole or 452 indazole ring to any extent, whether or not substituted on the 453 phenyl ring to any extent, including, but not limited to: 454 (I) JWH-167 (1-Pentyl-3-(phenylacetyl)indole). 455 (II) JWH-201 (1-Pentyl-3-(4-methoxyphenylacetyl)indole). 456 (III) JWH-203 (1-Pentyl-3-(2-chlorophenylacetyl)indole). 457 (IV) JWH-250 (1-Pentyl-3-(2-methoxyphenylacetyl)indole). 458 (V) JWH-251 (1-Pentyl-3-(2-methylphenylacetyl)indole). 459 (VI) JWH-302 (1-Pentyl-3-(3-methoxyphenylacetyl)indole). 460 (VII) Cannabipiperidiethanone. 461 (VIII) RCS-8 (1-(2-Cyclohexylethyl)-3-(2 462 methoxyphenylacetyl)indole). 463 f. Cyclohexylphenols.—Any compound containing a 464 cyclohexylphenol structure, with or without substitution at the 465 5-position of the phenolic ring to any extent, whether or not 466 substituted on the cyclohexyl ring to any extent, including, but 467 not limited to: 468 (I) CP 47,497 (2-(3-Hydroxycyclohexyl)-5-(2-methyloctan-2 469 yl)phenol). 470 (II) Cannabicyclohexanol (CP 47,497 dimethyloctyl (C8) 471 homologue). 472 (III) CP-55,940 (2-(3-Hydroxy-6-propanol-cyclohexyl)-5-(2 473 methyloctan-2-yl)phenol). 474 g. Benzoylindoles and Benzoylindazoles.—Any compound 475 containing a benzoylindole or benzoylindazole structure, with or 476 without substitution on the indole or indazole ring to any 477 extent, whether or not substituted on the phenyl ring to any 478 extent, including, but not limited to: 479 (I) AM-679 (1-Pentyl-3-(2-iodobenzoyl)indole). 480 (II) AM-694 (1-(5-Fluoropentyl)-3-(2-iodobenzoyl)indole). 481 (III) AM-1241 (1-[(N-Methyl-2-piperidinyl)methyl]-3-(2 482 iodo-5-nitrobenzoyl)indole). 483 (IV) Pravadoline (1-[2-(4-Morpholinyl)ethyl]-2-methyl-3-(4 484 methoxybenzoyl)indole). 485 (V) AM-2233 (1-[(N-Methyl-2-piperidinyl)methyl]-3-(2 486 iodobenzoyl)indole). 487 (VI) RCS-4 (1-Pentyl-3-(4-methoxybenzoyl)indole). 488 (VII) RCS-4 C4 homologue (1-Butyl-3-(4 489 methoxybenzoyl)indole). 490 (VIII) AM-630 (1-[2-(4-Morpholinyl)ethyl]-2-methyl-6-iodo 491 3-(4-methoxybenzoyl)indole). 492 h. Tetramethylcyclopropanoylindoles and 493 Tetramethylcyclopropanoylindazoles.—Any compound containing a 494 tetramethylcyclopropanoylindole or 495 tetramethylcyclopropanoylindazole structure, with or without 496 substitution on the indole or indazole ring to any extent, 497 whether or not substituted on the tetramethylcyclopropyl group 498 to any extent, including, but not limited to: 499 (I) UR-144 (1-Pentyl-3-(2,2,3,3 500 tetramethylcyclopropanoyl)indole). 501 (II) XLR11 (1-(5-Fluoropentyl)-3-(2,2,3,3 502 tetramethylcyclopropanoyl)indole). 503 (III) Chloro UR-144 (1-(Chloropentyl)-3-(2,2,3,3 504 tetramethylcyclopropanoyl)indole). 505 (IV) A-796,260 (1-[2-(4-Morpholinyl)ethyl]-3-(2,2,3,3 506 tetramethylcyclopropanoyl)indole). 507 (V) A-834,735 (1-[4-(Tetrahydropyranyl)methyl]-3-(2,2,3,3 508 tetramethylcyclopropanoyl)indole). 509 (VI) M-144 (1-(5-Fluoropentyl)-2-methyl-3-(2,2,3,3 510 tetramethylcyclopropanoyl)indole). 511 (VII) FUB-144 (1-(4-Fluorobenzyl)-3-(2,2,3,3 512 tetramethylcyclopropanoyl)indole). 513 (VIII) FAB-144 (1-(5-Fluoropentyl)-3-(2,2,3,3 514 tetramethylcyclopropanoyl)indazole). 515 (IX) XLR12 (1-(4,4,4-Trifluorobutyl)-3-(2,2,3,3 516 tetramethylcyclopropanoyl)indole). 517 (X) AB-005 (1-[(1-Methyl-2-piperidinyl)methyl]-3-(2,2,3,3 518 tetramethylcyclopropanoyl)indole). 519 i. Adamantoylindoles, Adamantoylindazoles, Adamantylindole 520 carboxamides, and Adamantylindazole carboxamides.—Any compound 521 containing an adamantoyl indole, adamantoyl indazole, adamantyl 522 indole carboxamide, or adamantyl indazole carboxamide structure, 523 with or without substitution on the indole or indazole ring to 524 any extent, whether or not substituted on the adamantyl ring to 525 any extent, including, but not limited to: 526 (I) AKB48 (N-Adamant-1-yl 1-pentylindazole-3-carboxamide). 527 (II) Fluoro AKB48 (N-Adamant-1-yl 1-(fluoropentyl)indazole 528 3-carboxamide). 529 (III) STS-135 (N-Adamant-1-yl 1-(5-fluoropentyl)indole-3 530 carboxamide). 531 (IV) AM-1248 (1-(1-Methylpiperidine)methyl-3-(1 532 adamantoyl)indole). 533 (V) AB-001 (1-Pentyl-3-(1-adamantoyl)indole). 534 (VI) APICA (N-Adamant-1-yl 1-pentylindole-3-carboxamide). 535 (VII) Fluoro AB-001 (1-(Fluoropentyl)-3-(1 536 adamantoyl)indole). 537 j. Quinolinylindolecarboxylates, 538 Quinolinylindazolecarboxylates, Quinolinylindolecarboxamides, 539 and Quinolinylindazolecarboxamides.—Any compound containing a 540 quinolinylindole carboxylate, quinolinylindazole carboxylate, 541 isoquinolinylindole carboxylate, isoquinolinylindazole 542 carboxylate, quinolinylindole carboxamide, quinolinylindazole 543 carboxamide, isoquinolinylindole carboxamide, or 544 isoquinolinylindazole carboxamide structure, with or without 545 substitution on the indole or indazole ring to any extent, 546 whether or not substituted on the quinoline or isoquinoline ring 547 to any extent, including, but not limited to: 548 (I) PB-22 (8-Quinolinyl 1-pentylindole-3-carboxylate). 549 (II) Fluoro PB-22 (8-Quinolinyl 1-(fluoropentyl)indole-3 550 carboxylate). 551 (III) BB-22 (8-Quinolinyl 1-(cyclohexylmethyl)indole-3 552 carboxylate). 553 (IV) FUB-PB-22 (8-Quinolinyl 1-(4-fluorobenzyl)indole-3 554 carboxylate). 555 (V) NPB-22 (8-Quinolinyl 1-pentylindazole-3-carboxylate). 556 (VI) Fluoro NPB-22 (8-Quinolinyl 1-(fluoropentyl)indazole 557 3-carboxylate). 558 (VII) FUB-NPB-22 (8-Quinolinyl 1-(4-fluorobenzyl)indazole 559 3-carboxylate). 560 (VIII) THJ (8-Quinolinyl 1-pentylindazole-3-carboxamide). 561 (IX) Fluoro THJ (8-Quinolinyl 1-(fluoropentyl)indazole-3 562 carboxamide). 563 k. Naphthylindolecarboxylates and 564 Naphthylindazolecarboxylates.—Any compound containing a 565 naphthylindole carboxylate or naphthylindazole carboxylate 566 structure, with or without substitution on the indole or 567 indazole ring to any extent, whether or not substituted on the 568 naphthyl ring to any extent, including, but not limited to: 569 (I) NM-2201 (1-Naphthalenyl 1-(5-fluoropentyl)indole-3 570 carboxylate). 571 (II) SDB-005 (1-Naphthalenyl 1-pentylindazole-3 572 carboxylate). 573 (III) Fluoro SDB-005 (1-Naphthalenyl 1 574 (fluoropentyl)indazole-3-carboxylate). 575 (IV) FDU-PB-22 (1-Naphthalenyl 1-(4-fluorobenzyl)indole-3 576 carboxylate). 577 (V) 3-CAF (2-Naphthalenyl 1-(2-fluorophenyl)indazole-3 578 carboxylate). 579 l. Naphthylindole carboxamides and Naphthylindazole 580 carboxamides.—Any compound containing a naphthylindole 581 carboxamide or naphthylindazole carboxamide structure, with or 582 without substitution on the indole or indazole ring to any 583 extent, whether or not substituted on the naphthyl ring to any 584 extent, including, but not limited to: 585 (I) NNEI (N-Naphthalen-1-yl 1-pentylindole-3-carboxamide). 586 (II) Fluoro-NNEI (N-Naphthalen-1-yl 1-(fluoropentyl)indole 587 3-carboxamide). 588 (III) Chloro-NNEI (N-Naphthalen-1-yl 1 589 (chloropentyl)indole-3-carboxamide). 590 (IV) MN-18 (N-Naphthalen-1-yl 1-pentylindazole-3 591 carboxamide). 592 (V) Fluoro MN-18 (N-Naphthalen-1-yl 1 593 (fluoropentyl)indazole-3-carboxamide). 594 m. Alkylcarbonyl indole carboxamides, Alkylcarbonyl 595 indazole carboxamides, Alkylcarbonyl indole carboxylates, and 596 Alkylcarbonyl indazole carboxylates.—Any compound containing an 597 alkylcarbonyl group, including 1-amino-3-methyl-1-oxobutan-2-yl, 598 1-methoxy-3-methyl-1-oxobutan-2-yl, 1-amino-1-oxo-3 599 phenylpropan-2-yl, 1-methoxy-1-oxo-3-phenylpropan-2-yl, with an 600 indole carboxamide, indazole carboxamide, indole carboxylate, or 601 indazole carboxylate, with or without substitution on the indole 602 or indazole ring to any extent, whether or not substituted on 603 the alkylcarbonyl group to any extent, including, but not 604 limited to: 605 (I) ADBICA, (N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1 606 pentylindole-3-carboxamide). 607 (II) Fluoro ADBICA (N-(1-Amino-3,3-dimethyl-1-oxobutan-2 608 yl)-1-(fluoropentyl)indole-3-carboxamide). 609 (III) Fluoro ABICA (N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1 610 (fluoropentyl)indole-3-carboxamide). 611 (IV) AB-PINACA (N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1 612 pentylindazole-3-carboxamide). 613 (V) Fluoro AB-PINACA (N-(1-Amino-3-methyl-1-oxobutan-2-yl) 614 1-(fluoropentyl)indazole-3-carboxamide). 615 (VI) ADB-PINACA (N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl) 616 1-pentylindazole-3-carboxamide). 617 (VII) Fluoro ADB-PINACA (N-(1-Amino-3,3-dimethyl-1 618 oxobutan-2-yl)-1-(fluoropentyl)indazole-3-carboxamide). 619 (VIII) AB-FUBINACA (N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1 620 (4-fluorobenzyl)indazole-3-carboxamide). 621 (IX) ADB-FUBINACA (N-(1-Amino-3,3-dimethyl-1-oxobutan-2 622 yl)-1-(4-fluorobenzyl)indazole-3-carboxamide). 623 (X) AB-CHMINACA (N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1 624 (cyclohexylmethyl)indazole-3-carboxamide). 625 (XI) MA-CHMINACA (N-(1-Methoxy-3-methyl-1-oxobutan-2-yl)-1 626 (cyclohexylmethyl)indazole-3-carboxamide). 627 (XII) MAB-CHMINACA (N-(1-Amino-3,3-dimethyl-1-oxobutan-2 628 yl)-1-(cyclohexylmethyl)indazole-3-carboxamide). 629 (XIII) AMB (N-(1-Methoxy-3-methyl-1-oxobutan-2-yl)-1 630 pentylindazole-3-carboxamide). 631 (XIV) Fluoro-AMB (N-(1-Methoxy-3-methyl-1-oxobutan-2-yl)-1 632 (fluoropentyl)indazole-3-carboxamide). 633 (XV) FUB-AMB (N-(1-Methoxy-3-methyl-1-oxobutan-2-yl)-1-(4 634 fluorobenzyl)indazole-3-carboxamide). 635 (XVI) MDMB-CHMINACA (N-(1-Methoxy-3,3-dimethyl-1-oxobutan 636 2-yl)-1-(cyclohexylmethyl)indazole-3-carboxamide). 637 (XVII) MDMB-FUBINACA (N-(1-Methoxy-3,3-dimethyl-1-oxobutan 638 2-yl)-1-(4-fluorobenzyl)indazole-3-carboxamide). 639 (XVIII) MDMB-CHMICA (N-(1-Methoxy-3,3-dimethyl-1-oxobutan 640 2-yl)-1-(cyclohexylmethyl)indole-3-carboxamide). 641 (XIX) PX-1 (N-(1-Amino-1-oxo-3-phenylpropan-2-yl)-1-(5 642 fluoropentyl)indole-3-carboxamide). 643 (XX) PX-2 (N-(1-Amino-1-oxo-3-phenylpropan-2-yl)-1-(5 644 fluoropentyl)indazole-3-carboxamide). 645 (XXI) PX-3 (N-(1-Amino-1-oxo-3-phenylpropan-2-yl)-1 646 (cyclohexylmethyl)indazole-3-carboxamide). 647 (XXII) PX-4 (N-(1-Amino-1-oxo-3-phenylpropan-2-yl)-1-(4 648 fluorobenzyl)indazole-3-carboxamide). 649 (XXIII) MO-CHMINACA (N-(1-Methoxy-3,3-dimethyl-1-oxobutan 650 2-yl)-1-(cyclohexylmethyl)indazole-3-carboxylate). 651 n. Cumylindolecarboxamides and Cumylindazolecarboxamides. 652 Any compound containing a N-(2-phenylpropan-2-yl) indole 653 carboxamide or N-(2-phenylpropan-2-yl) indazole carboxamide 654 structure, with or without substitution on the indole or 655 indazole ring to any extent, whether or not substituted on the 656 phenyl ring of the cumyl group to any extent, including, but not 657 limited to: 658 (I) CUMYL-PICA (N-(2-Phenylpropan-2-yl)-1-pentylindole-3 659 carboxamide). 660 (II) Fluoro CUMYL-PICA (N-(2-Phenylpropan-2-yl)-1 661 (fluoropentyl)indole-3-carboxamide). 662 o. Other Synthetic Cannabinoids.—Any material, compound, 663 mixture, or preparation that contains any quantity of a 664 Synthetic Cannabinoid, as described in sub-subparagraphs a.-n.: 665 (I) With or without modification or replacement of a 666 carbonyl, carboxamide, alkylene, alkyl, or carboxylate linkage 667 between either two core rings, or linkage between a core ring 668 and group structure, with or without the addition of a carbon or 669 replacement of a carbon; 670 (II) With or without replacement of a core ring or group 671 structure, whether or not substituted on the ring or group 672 structures to any extent; and 673 (III) Is a cannabinoid receptor agonist, unless 674 specifically excepted or unless listed in another schedule or 675 contained within a pharmaceutical product approved by the United 676 States Food and Drug Administration. 677 191. Substituted Cathinones.—Unless specifically excepted, 678 listed in another schedule, or contained within a pharmaceutical 679 product approved by the United States Food and Drug 680 Administration, any material, compound, mixture, or preparation, 681 including its salts, isomers, esters, or ethers, and salts of 682 isomers, esters, or ethers, whenever the existence of such salts 683 is possible within any of the following specific chemical 684 designations: 685 a. Any compound containing a 2-amino-1-phenyl-1-propanone 686 structure; 687 b. Any compound containing a 2-amino-1-naphthyl-1-propanone 688 structure; or 689 c. Any compound containing a 2-amino-1-thiophenyl-1 690 propanone structure, 691 692 whether or not the compound is further modified: 693 (I) With or without substitution on the ring system to any 694 extent with alkyl, alkylthio, thio, fused alkylenedioxy, alkoxy, 695 haloalkyl, hydroxyl, nitro, fused furan, fused benzofuran, fused 696 dihydrofuran, fused tetrahydropyran, fused alkyl ring, or halide 697 substituents; 698 (II) With or without substitution at the 3-propanone 699 position with an alkyl substituent or removal of the methyl 700 group at the 3-propanone position; 701 (III) With or without substitution at the 2-amino nitrogen 702 atom with alkyl, dialkyl, acetyl, or benzyl groups, whether or 703 not further substituted in the ring system; or 704 (IV) With or without inclusion of the 2-amino nitrogen atom 705 in a cyclic structure, including, but not limited to: 706 (A) Methcathinone. 707 (B) Ethcathinone. 708 (C) Methylone (3,4-Methylenedioxymethcathinone). 709 (D) 2,3-Methylenedioxymethcathinone. 710 (E) MDPV (3,4-Methylenedioxypyrovalerone). 711 (F) Methylmethcathinone. 712 (G) Methoxymethcathinone. 713 (H) Fluoromethcathinone. 714 (I) Methylethcathinone. 715 (J) Butylone (3,4-Methylenedioxy-alpha 716 methylaminobutyrophenone). 717 (K) Ethylone (3,4-Methylenedioxy-N-ethylcathinone). 718 (L) BMDP (3,4-Methylenedioxy-N-benzylcathinone). 719 (M) Naphyrone (Naphthylpyrovalerone). 720 (N) Bromomethcathinone. 721 (O) Buphedrone (alpha-Methylaminobutyrophenone). 722 (P) Eutylone (3,4-Methylenedioxy-alpha 723 ethylaminobutyrophenone). 724 (Q) Dimethylcathinone. 725 (R) Dimethylmethcathinone. 726 (S) Pentylone (3,4-Methylenedioxy-alpha 727 methylaminovalerophenone). 728 (T) Pentedrone (alpha-Methylaminovalerophenone). 729 (U) MDPPP (3,4-Methylenedioxy-alpha 730 pyrrolidinopropiophenone). 731 (V) MDPBP (3,4-Methylenedioxy-alpha 732 pyrrolidinobutyrophenone). 733 (W) MPPP (Methyl-alpha-pyrrolidinopropiophenone). 734 (X) PPP (Pyrrolidinopropiophenone). 735 (Y) PVP (Pyrrolidinovalerophenone) or 736 (Pyrrolidinopentiophenone). 737 (Z) MOPPP (Methoxy-alpha-pyrrolidinopropiophenone). 738 (AA) MPHP (Methyl-alpha-pyrrolidinohexanophenone). 739 (BB) F-MABP (Fluoromethylaminobutyrophenone). 740 (CC) Me-EABP (Methylethylaminobutyrophenone). 741 (DD) PBP (Pyrrolidinobutyrophenone). 742 (EE) MeO-PBP (Methoxypyrrolidinobutyrophenone). 743 (FF) Et-PBP (Ethylpyrrolidinobutyrophenone). 744 (GG) 3-Me-4-MeO-MCAT (3-Methyl-4-Methoxymethcathinone). 745 (HH) Dimethylone (3,4-Methylenedioxy-N,N 746 dimethylcathinone). 747 (II) 3,4-Methylenedioxy-N,N-diethylcathinone. 748 (JJ) 3,4-Methylenedioxy-N-acetylcathinone. 749 (KK) 3,4-Methylenedioxy-N-acetylmethcathinone. 750 (LL) 3,4-Methylenedioxy-N-acetylethcathinone. 751 (MM) Methylbuphedrone (Methyl-alpha 752 methylaminobutyrophenone). 753 (NN) Methyl-alpha-methylaminohexanophenone. 754 (OO) N-Ethyl-N-methylcathinone. 755 (PP) PHP (Pyrrolidinohexanophenone). 756 (QQ) PV8 (Pyrrolidinoheptanophenone). 757 (RR) Chloromethcathinone. 758 (SS) 4-Bromo-2,5-dimethoxy-alpha-aminoacetophenone. 759 192. Substituted Phenethylamines.—Unless specifically 760 excepted or unless listed in another schedule, or contained 761 within a pharmaceutical product approved by the United States 762 Food and Drug Administration, any material, compound, mixture, 763 or preparation, including its salts, isomers, esters, or ethers, 764 and salts of isomers, esters, or ethers, whenever the existence 765 of such salts is possible within any of the following specific 766 chemical designations, any compound containing a phenethylamine 767 structure, without a beta-keto group, and without a benzyl group 768 attached to the amine group, whether or not the compound is 769 further modified with or without substitution on the phenyl ring 770 to any extent with alkyl, alkylthio, nitro, alkoxy, thio, 771 halide, fused alkylenedioxy, fused furan, fused benzofuran, 772 fused dihydrofuran, or fused tetrahydropyran substituents, 773 whether or not further substituted on a ring to any extent, with 774 or without substitution at the alpha or beta position by any 775 alkyl substituent, with or without substitution at the nitrogen 776 atom, and with or without inclusion of the 2-amino nitrogen atom 777 in a cyclic structure, including, but not limited to: 778 a. 2C-B (4-Bromo-2,5-dimethoxyphenethylamine). 779 b. 2C-E (4-Ethyl-2,5-dimethoxyphenethylamine). 780 c. 2C-T-4 (4-Isopropylthio-2,5-dimethoxyphenethylamine). 781 d. 2C-C (4-Chloro-2,5-dimethoxyphenethylamine). 782 e. 2C-T (4-Methylthio-2,5-dimethoxyphenethylamine). 783 f. 2C-T-2 (4-Ethylthio-2,5-dimethoxyphenethylamine). 784 g. 2C-T-7 (4-(n)-Propylthio-2,5-dimethoxyphenethylamine). 785 h. 2C-I (4-Iodo-2,5-dimethoxyphenethylamine). 786 i. 2C-D (4-Methyl-2,5-dimethoxyphenethylamine). 787 j. 2C-H (2,5-Dimethoxyphenethylamine). 788 k. 2C-N (4-Nitro-2,5-dimethoxyphenethylamine). 789 l. 2C-P (4-(n)-Propyl-2,5-dimethoxyphenethylamine). 790 m. MDMA (3,4-Methylenedioxymethamphetamine). 791 n. MBDB (Methylbenzodioxolylbutanamine) or (3,4 792 Methylenedioxy-N-methylbutanamine). 793 o. MDA (3,4-Methylenedioxyamphetamine). 794 p. 2,5-Dimethoxyamphetamine. 795 q. Fluoroamphetamine. 796 r. Fluoromethamphetamine. 797 s. MDEA (3,4-Methylenedioxy-N-ethylamphetamine). 798 t. DOB (4-Bromo-2,5-dimethoxyamphetamine). 799 u. DOC (4-Chloro-2,5-dimethoxyamphetamine). 800 v. DOET (4-Ethyl-2,5-dimethoxyamphetamine). 801 w. DOI (4-Iodo-2,5-dimethoxyamphetamine). 802 x. DOM (4-Methyl-2,5-dimethoxyamphetamine). 803 y. PMA (4-Methoxyamphetamine). 804 z. N-Ethylamphetamine. 805 aa. 3,4-Methylenedioxy-N-hydroxyamphetamine. 806 bb. 5-Methoxy-3,4-methylenedioxyamphetamine. 807 cc. PMMA (4-Methoxymethamphetamine). 808 dd. N,N-Dimethylamphetamine. 809 ee. 3,4,5-Trimethoxyamphetamine. 810 ff. 4-APB (4-(2-Aminopropyl)benzofuran). 811 gg. 5-APB (5-(2-Aminopropyl)benzofuran). 812 hh. 6-APB (6-(2-Aminopropyl)benzofuran). 813 ii. 7-APB (7-(2-Aminopropyl)benzofuran). 814 jj. 4-APDB (4-(2-Aminopropyl)-2,3-dihydrobenzofuran). 815 kk. 5-APDB (5-(2-Aminopropyl)-2,3-dihydrobenzofuran). 816 ll. 6-APDB (6-(2-Aminopropyl)-2,3-dihydrobenzofuran). 817 mm. 7-APDB (7-(2-Aminopropyl)-2,3-dihydrobenzofuran). 818 nn. 4-MAPB (4-(2-Methylaminopropyl)benzofuran). 819 oo. 5-MAPB (5-(2-Methylaminopropyl)benzofuran). 820 pp. 6-MAPB (6-(2-Methylaminopropyl)benzofuran). 821 qq. 7-MAPB (7-(2-Methylaminopropyl)benzofuran). 822 rr. 5-EAPB (5-(2-Ethylaminopropyl)benzofuran). 823 ss. 5-MAPDB (5-(2-Methylaminopropyl)-2,3 824 dihydrobenzofuran), 825 826 which does not include phenethylamine, mescaline as described in 827 subparagraph 20., substituted cathinones as described in 828 subparagraph 191., N-Benzyl phenethylamine compounds as 829 described in subparagraph 193., or methamphetamine as described 830 in subparagraph (2)(c)5. 831 193. N-Benzyl Phenethylamine Compounds.—Unless specifically 832 excepted or unless listed in another schedule, or contained 833 within a pharmaceutical product approved by the United States 834 Food and Drug Administration, any material, compound, mixture, 835 or preparation, including its salts, isomers, esters, or ethers, 836 and salts of isomers, esters, or ethers, whenever the existence 837 of such salts is possible within any of the following specific 838 chemical designations, any compound containing a phenethylamine 839 structure without a beta-keto group, with substitution on the 840 nitrogen atom of the amino group with a benzyl substituent, with 841 or without substitution on the phenyl or benzyl ring to any 842 extent with alkyl, alkoxy, thio, alkylthio, halide, fused 843 alkylenedioxy, fused furan, fused benzofuran, or fused 844 tetrahydropyran substituents, whether or not further substituted 845 on a ring to any extent, with or without substitution at the 846 alpha position by any alkyl substituent, including, but not 847 limited to: 848 a. 25B-NBOMe (4-Bromo-2,5-dimethoxy-[N-(2 849 methoxybenzyl)]phenethylamine). 850 b. 25B-NBOH (4-Bromo-2,5-dimethoxy-[N-(2 851 hydroxybenzyl)]phenethylamine). 852 c. 25B-NBF (4-Bromo-2,5-dimethoxy-[N-(2 853 fluorobenzyl)]phenethylamine). 854 d. 25B-NBMD (4-Bromo-2,5-dimethoxy-[N-(2,3 855 methylenedioxybenzyl)]phenethylamine). 856 e. 25I-NBOMe (4-Iodo-2,5-dimethoxy-[N-(2 857 methoxybenzyl)]phenethylamine). 858 f. 25I-NBOH (4-Iodo-2,5-dimethoxy-[N-(2 859 hydroxybenzyl)]phenethylamine). 860 g. 25I-NBF (4-Iodo-2,5-dimethoxy-[N-(2 861 fluorobenzyl)]phenethylamine). 862 h. 25I-NBMD (4-Iodo-2,5-dimethoxy-[N-(2,3 863 methylenedioxybenzyl)]phenethylamine). 864 i. 25T2-NBOMe (4-Methylthio-2,5-dimethoxy-[N-(2 865 methoxybenzyl)]phenethylamine). 866 j. 25T4-NBOMe (4-Isopropylthio-2,5-dimethoxy-[N-(2 867 methoxybenzyl)]phenethylamine). 868 k. 25T7-NBOMe (4-(n)-Propylthio-2,5-dimethoxy-[N-(2 869 methoxybenzyl)]phenethylamine). 870 l. 25C-NBOMe (4-Chloro-2,5-dimethoxy-[N-(2 871 methoxybenzyl)]phenethylamine). 872 m. 25C-NBOH (4-Chloro-2,5-dimethoxy-[N-(2 873 hydroxybenzyl)]phenethylamine). 874 n. 25C-NBF (4-Chloro-2,5-dimethoxy-[N-(2 875 fluorobenzyl)]phenethylamine). 876 o. 25C-NBMD (4-Chloro-2,5-dimethoxy-[N-(2,3 877 methylenedioxybenzyl)]phenethylamine). 878 p. 25H-NBOMe (2,5-Dimethoxy-[N-(2 879 methoxybenzyl)]phenethylamine). 880 q. 25H-NBOH (2,5-Dimethoxy-[N-(2 881 hydroxybenzyl)]phenethylamine). 882 r. 25H-NBF (2,5-Dimethoxy-[N-(2 883 fluorobenzyl)]phenethylamine). 884 s. 25D-NBOMe (4-Methyl-2,5-dimethoxy-[N-(2 885 methoxybenzyl)]phenethylamine), 886 887 which does not include substituted cathinones as described in 888 subparagraph 191. 889 194. Substituted Tryptamines.—Unless specifically excepted 890 or unless listed in another schedule, or contained within a 891 pharmaceutical product approved by the United States Food and 892 Drug Administration, any material, compound, mixture, or 893 preparation containing a 2-(1H-indol-3-yl)ethanamine, for 894 example tryptamine, structure with or without mono- or di 895 substitution of the amine nitrogen with alkyl or alkenyl groups, 896 or by inclusion of the amino nitrogen atom in a cyclic 897 structure, whether or not substituted at the alpha position with 898 an alkyl group, whether or not substituted on the indole ring to 899 any extent with any alkyl, alkoxy, halo, hydroxyl, or acetoxy 900 groups, including, but not limited to: 901 a. Alpha-Ethyltryptamine. 902 b. Bufotenine. 903 c. DET (Diethyltryptamine). 904 d. DMT (Dimethyltryptamine). 905 e. MET (N-Methyl-N-ethyltryptamine). 906 f. DALT (N,N-Diallyltryptamine). 907 g. EiPT (N-Ethyl-N-isopropyltryptamine). 908 h. MiPT (N-Methyl-N-isopropyltryptamine). 909 i. 5-Hydroxy-AMT (5-Hydroxy-alpha-methyltryptamine). 910 j. 5-Hydroxy-N-methyltryptamine. 911 k. 5-MeO-MiPT (5-Methoxy-N-methyl-N-isopropyltryptamine). 912 l. 5-MeO-AMT (5-Methoxy-alpha-methyltryptamine). 913 m. Methyltryptamine. 914 n. 5-MeO-DMT (5-Methoxy-N,N-dimethyltryptamine). 915 o. 5-Me-DMT (5-Methyl-N,N-dimethyltryptamine). 916 p. 5-MeO-DiPT (5-Methoxy-N,N-Diisopropyltryptamine). 917 q. DiPT (N,N-Diisopropyltryptamine). 918 r. DPT (N,N-Dipropyltryptamine). 919 s. 4-Hydroxy-DiPT (4-Hydroxy-N,N-diisopropyltryptamine). 920 t. 5-MeO-DALT (5-Methoxy-N,N-Diallyltryptamine). 921 u. 4-AcO-DMT (4-Acetoxy-N,N-dimethyltryptamine). 922 v. 4-AcO-DiPT (4-Acetoxy-N,N-diisopropyltryptamine). 923 w. 4-Hydroxy-DET (4-Hydroxy-N,N-diethyltryptamine). 924 x. 4-Hydroxy-MET (4-Hydroxy-N-methyl-N-ethyltryptamine). 925 y. 4-Hydroxy-MiPT (4-Hydroxy-N-methyl-N 926 isopropyltryptamine). 927 z. Methyl-alpha-ethyltryptamine. 928 aa. Bromo-DALT (Bromo-N,N-diallyltryptamine), 929 930 which does not include tryptamine, psilocyn as described in 931 subparagraph 34., or psilocybin as described in subparagraph 33. 932 195. Substituted Phenylcyclohexylamines.—Unless 933 specifically excepted or unless listed in another schedule, or 934 contained within a pharmaceutical product approved by the United 935 States Food and Drug Administration, any material, compound, 936 mixture, or preparation containing a phenylcyclohexylamine 937 structure, with or without any substitution on the phenyl ring, 938 any substitution on the cyclohexyl ring, any replacement of the 939 phenyl ring with a thiophenyl or benzothiophenyl ring, with or 940 without substitution on the amine with alkyl, dialkyl, or alkoxy 941 substituents, inclusion of the nitrogen in a cyclic structure, 942 or any combination of the above, including, but not limited to: 943 a. BTCP (Benzothiophenylcyclohexylpiperidine) or BCP 944 (Benocyclidine). 945 b. PCE (N-Ethyl-1-phenylcyclohexylamine)(Ethylamine analog 946 of phencyclidine). 947 c. PCPY (N-(1-Phenylcyclohexyl)-pyrrolidine)(Pyrrolidine 948 analog of phencyclidine). 949 d. PCPr (Phenylcyclohexylpropylamine). 950 e. TCP (1-[1-(2-Thienyl)-cyclohexyl]-piperidine)(Thiophene 951 analog of phencyclidine). 952 f. PCEEA (Phenylcyclohexyl(ethoxyethylamine)). 953 g. PCMPA (Phenylcyclohexyl(methoxypropylamine)). 954 h. Methoxetamine. 955 i. 3-Methoxy-PCE ((3-Methoxyphenyl)cyclohexylethylamine). 956 j. Bromo-PCP ((Bromophenyl)cyclohexylpiperidine). 957 k. Chloro-PCP ((Chlorophenyl)cyclohexylpiperidine). 958 l. Fluoro-PCP ((Fluorophenyl)cyclohexylpiperidine). 959 m. Hydroxy-PCP ((Hydroxyphenyl)cyclohexylpiperidine). 960 n. Methoxy-PCP ((Methoxyphenyl)cyclohexylpiperidine). 961 o. Methyl-PCP ((Methylphenyl)cyclohexylpiperidine). 962 p. Nitro-PCP ((Nitrophenyl)cyclohexylpiperidine). 963 q. Oxo-PCP ((Oxophenyl)cyclohexylpiperidine). 964 r. Amino-PCP ((Aminophenyl)cyclohexylpiperidine). 965 196. W-15, 4-chloro-N-[1-(2-phenylethyl)-2 966 piperidinylidene]-benzenesulfonamide. 967 197. W-18, 4-chloro-N-[1-[2-(4-nitrophenyl)ethyl]-2 968 piperidinylidene]-benzenesulfonamide. 969 198. AH-7921, 3,4-dichloro-N-[[1 970 (dimethylamino)cyclohexyl]methyl]-benzamide. 971 199. U47700, trans-3,4-dichloro-N-[2 972 (dimethylamino)cyclohexyl]-N-methyl-benzamide. 973 200. MT-45, 1-cyclohexyl-4-(1,2-diphenylethyl)-piperazine, 974 dihydrochloride. 975 Section 2. This act shall take effect upon becoming a law.